Heterogeneous worldwide access and pricing of Tafamidis

Click to increase image sizeClick to decrease image size

Disclosure statement

AW- None

DB: Cardiac ATTR Amyloidosis Fellowship grant funded by International Society of Amyloidosis.

NF: None

PGP: Reports speaking fees from Alnylam Pharmaceuticals, Bridgebio, Ionis Pharmaceuticals, AstraZeneca, NovoNordisk and Pfizer; consulting fees from Alexion, Alnylam Pharmaceuticals, AstraZeneca, ATTRalus, Bridgebio, Intellia, Neuroimmune, NovoNordisk, and Pfizer; and research/educational support to his institution from Alnylam Pharmaceuticals, Bridgebio, and Pfizer.

MG: None

AK: None

TD: Reports research grants or consultant fees from Astra Zeneca, Alnylam, Akcea, Ionis, GSK, Prothena, Pfizer, Neurimmune.

YS: None

MM: Reports grant support from NIH R01HL139671 and RO1AG081582, grants from Alnylam, Pfizer, Eidos, Attralus; and personal fees from Alnylam, Astra Zeneca, Ionis, Intellia, and Novo-Nordisk.

Figure 1. A world map illustrating Tafamidis availability for the treatment of ATTR cardiac amyloidosis. Green indicates countries where Tafamidis is available with labels for specific countries indicating the annual price list of Tafamidis where it is available for the treatment of ATTR cardiac amyloidosis. Dark green indicates countries where Tafamidis is available but not clear if approved for cardiac amyloidosis (list provided by the manufacturer). red indicates countries where Tafamidis is not available. Data for prices shown was obtained from experts in respective countries and or data from the following sources: USA Canada Italy Spain France Sweden Argentina Greece.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.